Hopes that anti-TIGIT drugs could be the next step forward in non-small cell lung cancer immunotherapy have been dealt another blow by the failure of Roche’s SKYSCRAPER-06 study.
Roche’s SKYSCRAPER-06 Failure Is Another Blow For TIGIT
It is not all over for Roche’s hopes for tiragolumab in frontline NSCLC but it may soon be.
